Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1227-1229, 2003; 10.1373/49.7.1227
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chace, D. H.
Right arrow Articles by Liotta, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chace, D. H.
Right arrow Articles by Liotta, L. A.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2003;49:1227-1229.)
© 2003 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection Has Already Arrived

Donald H. Chace

Neo Gen Screening, PO Box 219, 90 Emerson Lane, Bridgeville, PA 15017

E-mail dchace@neogenscreening.com

The first 20% of the full text of this article appears below.

I read with great interest the editorial entitled "Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection" by Petricoin and Liotta (1). These authors provided provocative commentary on current and new mass spectrometry (MS)-based approaches in clinical chemistry related to detection and characterization of various diseases, with emphasis on proteomics and cancer diagnostics. They discuss MS as disruptive or nonlinear because of the excitement and fear that are generated by its use. The editorial correctly implies that the potential contributions of MS in clinical chemistry are staggering.

I suggest that these authors have a somewhat narrow view of MS applications in clinical chemistry limited to their area of expertise. Furthermore, I would disagree somewhat with the statement that MS-based approaches are disruptive and nonlinear. Petricoin and Liotta omitted the extensive historic role of MS in clinical chemistry, including the numerous contributions and advancements in the previous two decades. Bruns et al. accurately describe the recent and important contributions of mass spectrometry and included timely manuscripts in the text, Molecular Testing in Laboratory Medicine (2). Dozens of other articles have appeared in Clinical Chemistry and other journals regarding MS applications in clinical chemistry, as . . . [Full Text of this Article]

Emanuel F. Petricoin1,a and Lance A. Liotta2

1 Food and Drug Administration, Bldg 29a, Room 2D12, 8800 Rockville Pike, Bethesda, MD 20892

2 National Cancer Institute, Laboratory of Pathology, NIH, 10 Center Drive, Bethesda, MD 20892-1500

aAuthor for correspondence. E-mail petricoin@cber.fda.gov.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.